A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support

Haematologica

Volumn 94, Issue 9, 2009, Pages 1274-1281

  Vangsted, Annette J ^a,b   Klausen, Tobias W ^b   Gimsing, Peter ^c   Andersen, Niels F ^d   Abildgaard, Niels ^e   Gregersen, Henrik ^f   Vogel, Ulla ^g,h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^h ROSKILDE UNIVERSITY   (Denmark)

Author keywords

Interferon; Multiple myeloma; NF B; Polymorphism; Treatment outcome

Indexed keywords

ALPHA INTERFERON; CD3E MOLECULE EPSILON ASSOCIATED PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELPHALAN; NUCLEIC ACID BINDING PROTEIN; PHOSPHOPROTEIN; PROTEIN PHOSPHATE 1 REGULATORY (INHIBITORY) SUBUNIT 13 LIKE PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; INDEL MUTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; SURVIVAL TIME; WILD TYPE;

ADULT; AGED; ALLELES; ANTIGENS, CD3; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 70349092296     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.004572     Document Type: Article

References (24)

1. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-936 (Pubitemid 46638847)
2. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998;102:495-502. (Pubitemid 28346591)
3. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113:1020-1034
4. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264
5. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436 (Pubitemid 44050137)
6. Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, et al. The polymorphism IL- 1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 2009;43:539-545
7. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007;120:1036-1045 (Pubitemid 46214303)
8. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006;15:519-529 (Pubitemid 43205418)
9. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002;123:1793-1803 (Pubitemid 35408303)
10. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin- 6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376 (Pubitemid 28467565)
11. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey- Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45. (Pubitemid 38072133)
12. Yamazaki T, Hamano Y, Tashiro H, Itoh K, Nakano H, Miyatake S, et al. CAST, a novel CD3epsilon-binding protein transducing activation signal for interleukin-2 production in T cells. J Biol Chem 1999;274:18173-18180 (Pubitemid 129519212)
13. Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA. Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis 2001;22:899-904. (Pubitemid 32514955)
14. Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, et al. A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of postmenopausal breast cancer before age 55. Carcinogenesis 2003;24:899-904. (Pubitemid 36748906)
15. Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, et al. Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res 2004;546:65-74. (Pubitemid 38130220)
16. Yang JP, Hori M, Sanda T, Okamoto T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem 1999;274:15662-15670 (Pubitemid 129518922)
17. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11. (Pubitemid 30017218)
18. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389-396
19. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008;112:129-135
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
21. Saber AT, Nielsen LR, Dictor M, Hagmar L, Mikoczy Z, Wallin H. Kras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Lett 1998;126:59-65. (Pubitemid 28142972)
22. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007;624:88-100.
23. Labeur M, Refojo D, Wolfel B, Stalla J, Vargas V, Theodoropoulou M, et al. Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J Endocrinol 2008;199:177-189
24. Sirohi B, Powles R, Lawrence D, Treleaven J, Kulkarni S, Leary A, et al. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferonalpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. Ann Oncol 2007;18:1388-1394 (Pubitemid 47305014)